Through its collaboration with Variational AI, Rakovina Therapeutics utilized the Enki™ generative AI platform to identify novel small-molecule candidates predicted to meet a defined target product ...

With an estimated 1.5 million new cases and 397,000 deaths worldwide, prostate cancer is the world's second most frequent cancer and the fifth leading cause of cancer death among men in 2022. Hormone ...

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced three abstracts to be presented at the 36 th EORTC-NCI-AACR (ENA) Symposium 2024 from October 23-25, in Barcelona, Spain ...

Revolution Medicines Inc. (NASDAQ:RVMD) is one of the best high short interest stocks with huge upside potential. On June 30, Revolution Medicines and Summit Therapeutics Inc. (NASDAQ:SMMT) announced ...

For the first time, scientists have identified promising drug candidates that bind irreversibly with a notoriously undruggable cancer protein target, permanently blocking it. Transcription factors are ...

Phase 1 Clinical Trial in Patients with Advanced B-Cell Malignancies Expected to Begin in the Second Half of 2022 NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based ...

Iambic Therapeutics said on Monday early-stage data of its experimental drug showed anti-tumor activity in heavily pretreated cancer patients with mutations in the HER2 gene.

Acquisition significantly enhances the Company’s pipeline by adding novel assets in acute and chronic anticoagulation settings Company is strategically poised to deliver differentiated therapeutics ...

For the first time scientists have identified promising drug candidates that bind irreversibly with a notoriously "undruggable" cancer protein target, permanently blocking it. Transcription factors ...